Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists

Matthew J. Price, Colin M. Barker

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist is the cornerstone of management in patients with acute coronary syndrome and those with coronary artery disease who have undergone coronary stent implantation. Clopidogrel is the most commonly used P2Y12 antagonist. Despite clopidogrels clinical effectiveness in reducing recurrent cardiovascular events in patients with coronary artery disease, the pharmacodynamic effect of clopidogrel is heterogeneous. Various platelet function tests that provide a quantitative measure of the downstream effects of clopidogrel on the P2Y12 receptor are available. The consistent observation that a lack of clopidogrel effect based on these tests is associated with poor clinical outcome has led to the promise of an individualized, patient-centered approach to antiplatelet therapy. Over the past few years, a wealth of data have helped bring this promise closer to reality, and upcoming clinical trials of platelet function testing could at last bring personalized medicine into routine clinical practice.

Original languageEnglish (US)
Pages (from-to)43-51
Number of pages9
JournalBiomarkers in Medicine
Issue number1
StatePublished - Feb 2011


  • clopidogrel
  • P2Yreceptor
  • platelet
  • platelet function testing
  • prasugrel
  • stent
  • thienopyridines

ASJC Scopus subject areas

  • Clinical Biochemistry
  • Biochemistry, medical
  • Drug Discovery


Dive into the research topics of 'Functional testing methods for the antiplatelet effect of P2Y12 receptor antagonists'. Together they form a unique fingerprint.

Cite this